Treatment modification with sunitinib in first-line (1L) metastatic renal cell carcinoma (mRCC): An analysis of the STAR-TOR registry.

Authors

null

Martin Boegemann

University of Muenster Medical Center, Münster, Germany

Martin Boegemann , Marcus Hubbe , Despina Thomaidou , Stuart Blackburn , Nawal Bent-Ennakhil , Robert Wood , Danielle Bargo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 602)

DOI

10.1200/JCO.2018.36.6_suppl.602

Abstract #

602

Poster Bd #

F17

Abstract Disclosures

Similar Posters

Poster

2015 ASCO Annual Meeting

Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).

Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).

First Author: Georg A. Bjarnason

Poster

2013 Genitourinary Cancers Symposium

Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma.

Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma.

First Author: Yana George Najjar